- NeoVentures Biotechnology’s Aptamarker platform revolutionizes clinical trials by introducing personalized and predictive inclusion and exclusion criteria.
- Aptamarkers are trained using biological samples and participants’ treatment responses, enabling a cost-effective qPCR test for screening individuals entering clinical trials.
- The predictive capabilities of Aptamarkers allow researchers to tailor inclusion criteria for positive treatment responses and exclusion criteria for those prone to side effects, enhancing trial success rates, participant safety, and overall efficiency in drug development.
Clinical trials are pivotal stages in the journey of drug development, providing invaluable insights into a treatment’s efficacy and safety. The traditional approach to clinical trial design involves defining strict inclusion and exclusion criteria based on general population characteristics. However, the dynamic nature of individual responses to treatments necessitates a more personalized and predictive strategy. NeoVentures Biotechnology’s Aptamarker platform is revolutionizing the landscape of clinical trials by offering a sophisticated solution to tailor inclusion and exclusion criteria with unprecedented precision.
The Dynamics of Clinical Trials
The heart of clinical trials lies in the generation of new information, but the journey is far from uniform for every participant. Some individuals may experience unexpected side effects, while others may respond exceptionally well to the treatment. Recognizing this variability, Aptamarker introduces a paradigm shift by allowing the training of aptamarkers to predict individual clinical trial outcomes.
Aptamarker Training for Personalized Predictions
The process begins by applying the Aptamarker library to biological samples obtained from individuals entering a clinical trial. This pre-treatment application provides a baseline understanding of the participants’ biomolecular landscape. Simultaneously, the platform requires knowledge of these individuals’ reactions to the treatment during the trial. This dual-input approach is essential for training Aptamarkers to recognize specific biomarkers associated with treatment response or adverse reactions.
Cost-Effective Screening through qPCR Testing
Once the Aptamarkers are trained, their translation to a simple quantitative polymerase chain reaction (qPCR) test becomes a game-changer. This transformation enables a cost-effective and efficient screening process for individuals entering clinical trials. The qPCR test, based on the Aptamarker library, acts as a diagnostic tool, providing rapid insights into an individual’s likelihood of responding favorably to the treatment or experiencing undesirable side effects.
Tailoring Inclusion and Exclusion Criteria
Aptamarker’s predictive capabilities empower researchers to identify individuals with a predisposition for positive treatment responses. By screening potential participants based on the Aptamarker qPCR test, clinical trials can be designed to include individuals who are more likely to benefit from the treatment, enhancing the overall success rate of the trial and optimizing resource utilization.
Conversely, Aptamarker screening can identify individuals prone to undesirable side effects or non-responsiveness. This exclusionary approach prioritizes participant safety and streamlines the clinical trial process by eliminating candidates less likely to derive benefits from the treatment. This not only enhances the overall safety profile of the trial but also contributes to a more efficient and cost-effective drug development pipeline.
Repositioning Clinical Trials for Different Indications
Aptamarker’s flexibility extends beyond initial trial design. The insights gained from the biomolecular profiling of participants can facilitate the repositioning of clinical trials for different indications. By understanding the unique responses within a population, researchers can explore alternative therapeutic applications without starting from scratch, potentially accelerating the development of treatments for various conditions.
In conclusion, NeoVentures Biotechnology’s Aptamarker platform is reshaping the future of clinical trials. By introducing a personalized and predictive dimension to inclusion and exclusion criteria, Aptamarkers bring a level of precision that was once unimaginable. This approach not only enhances the efficiency and success rates of clinical trials but also ensures a safer and more cost-effective drug development process. As we embrace the era of Aptamarkers, we embark on a journey toward a new standard of personalized medicine and targeted therapeutic interventions, ultimately advancing the frontiers of healthcare innovation.
Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases.